Clinical Trial Update: Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the safety and immunogenicity of the EBA-175 RII-NG malaria vaccine administered intramuscularly.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plasmodium Falciparum Malaria

Drugs mentioned

• EBA-175 RII-NG malaria vaccine (EBA-175 RII-NG malaria vaccine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: Plasmodium Falciparum Malaria | Phase 1 | Status: COMPLETED